A surgical system including an implantable medical device having a size and shape. The surgical device having a substrate and a coating that covers at least a portion of the substrate. The coating including collagen, glycerin and a hemostatic agent. The substrate including a first piece and a second piece that is joined with the first piece. The first piece and the second piece forming a pocket having a cavity and an opening that is in communication with the cavity. The device being pre-formed such that a size and shape of the cavity conforms to the size and shape of the implantable medical device.

The invention relates to a method for assembling a clay-nanoparticle gel suitable for loading with one or more molecule species such that they are spatially structured therein, and a method for forming a clay-nanoparticle gel comprising one or more spatially structured molecule species. The invention further relates to structured clay nanoparticle gel and their use, for example in treatment.

Compositions and methods for protecting BHV from SVD mechanisms, including non-calcific SVD mechanisms, are provided.

Methods and products for maintaining a target pH range of an environment including at least one organism are provided. A method can include releasing a carbon source to the environment. A method can further include allowing the carbon source to be metabolized by the at least one organism and lower a pH of the environment. The method can also include releasing a nitrogen source to the environment. The method can additionally include allowing the nitrogen source to be metabolized by the at least one organism and increase the pH of the environment. The releasing of the carbon source to the environment and the releasing of the nitrogen source to the environment can be selectively timed to control the pH of the environment to the target pH range of the environment.

The application discloses a use of nanofiber membrane in the preparation of medical apparatus for anti-adhesion after a surgery, wherein small molecule drug, inhibiting vascular endothelial growth factor and/or inhibiting vascular endothelial growth factor receptor, is loaded into the nanofiber membrane. The nanofiber membrane provided in the present application has the following advantages: it has good biocompatibility, excellent mechanical properties, excellent flexibility and smoothness when exposed to water, good air permeability, and has the ability to effectively prevent adhesion between the heart and surrounding tissues. In addition, it can also be applied to other surgical operations, such as prevention of adhesions in the abdominal cavity, pelvis, and tendons.

Provided herein are oxazolidinone derivatives that can exhibit anti-microbial activity and/or activity as biofilm modulating agents (e.g., activity as biofilm inhibitors and/or activity as biofilm dispersal agents). The compounds can exhibit potent activity anti-microbial activity (e.g., potent activity against Gram-positive positive bacteria including methicillin-resistant Staphylococcus aureus). The compounds can exhibit potent activity against biofilms. In some cases, the compounds can exhibit both anti-microbial activity and biofilm modulation properties.

Provided herein are compounds that can exhibit activity as biofilm modulating agents (e.g., activity as biofilm inhibitors and/or activity as biofilm dispersal agents). The compounds can exhibit potent activity against Gram positive biofilms. The compounds can also exhibit activity against Gram negative biofilms. In some cases, the compounds can exhibit both biofilm modulation properties and antimicrobial activity. Compositions comprising these compounds, as well as methods of using thereof, are also described. For example, the compounds described herein can be used in human and animal health (e.g., for the treatment of infection), agriculture, marine coatings, and other coating applications related to prevention of biofilm (e.g., dental, medical, etc.).

A composition for providing or maintaining a healthy skin microbiota and methods of providing or maintaining a healthy skin microbiota are disclosed. The composition can be a prebiotic composition that can include a carrier and a skin microbiota balancing agent. In some aspects, the skin microbiota balancing agent can include at least one combination of carbohydrate sources including a first carbohydrate source and a second carbohydrate source. The skin microbiota balancing agent can be configured to provide at least two of the following desired ratios: a first desired ratio of Corynebaderium to Staphylococcus of 1.3, a second desired ratio of Corynebaderium to Micrococcus of 1.4, and a third desired ratio of Staphylococcus to Micrococcus of 1.1. The carbohydrate sources may be D-alanine, D-threonine, L-alanyl-glycine, succinic acid, α-keto-glutaric acid, m-tantaric acid, bromo succinic acid, mucic acid, phenylethyl-amine, inulin, oxalic acid, pectin, Tween 40 etc.

Medical device are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is water-soluble. In further embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has a molecular weight of from 80 to 750 or has more than four hydroxyl groups.

The present invention relates to a method for dynamic filtration of a cross-linked biopolymer-based hydrogel to remove unwanted molecules from the gel. In particular, the invention relates to dynamic filtration of a hyaluronic acid hydrogel using a dynamic filtration construction with rotating and semipermeable filter discs.